Antibody-drug conjugates advance into early therapy
Astrazeneca/Daiichi’s Enhertu and Roche’s Polivy both score in pivotal trials that could see them threaten early-line incumbents.
Biopharma’s ballooning licensing deal bill
Up-front costs are higher than ever, with preclinical and phase 2 assets showing the most price inflation, according to a new analysis of licensing deal trends.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
Key third-quarter readouts for big pharma
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
After Immunogen and Sutro, Bristol buys into the folate story
The deal puts more support behind targeting folate receptor α, a long troubled target, with antibody-drug conjugates.
Bristol and Glaxo’s oncology deals vault into the top five
Two huge up-front fees this week, for an anti-Tigit MAb and an antibody-drug conjugate, show that early-stage oncology assets are still hot.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Esmo Breast Cancer – Astra and Daiichi square up to Gilead
Datopotamab, a project with a very similar mechanism to Trodelvy, shows impressive early data in triple-negative breast cancer.
Macrogenics takes another shot at a novel immune checkpoint
Having failed with orlotamab, and with enoblituzumab’s potential narrowing, Macrogenics generates interest around MGC018.
